Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.66 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | PLAU | P00749 | 1/20 | 0.62 |
| ▸ | PLAT | P00750 | 1/20 | 0.62 |
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084689 | 1.00 | ITGB3 (0.66) | ITGB3ITGA2BF2PLAUPLAT | |
| SCHEMBL26661077 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB | |
| SCHEMBL219151 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB | |
| SCHEMBL479010 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB | |
| SCHEMBL7372270 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB | |
| SCHEMBL220648 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BTACR1CTSLCTSB | |
| Aniline SCHEMBL8510048 | 0.90 | ALDH1A1 (0.59) | ITGB3ITGA2BF2PLAUPLAT | |
| SCHEMBL20187266 | 0.90 | ITGB3 (0.56) | ITGB3ITGA2BF2PLAUPLAT | |
| SCHEMBL18228971 | 0.90 | ITGB3 (0.56) | ITGB3ITGA2BF2PLAUPLAT | |
| SCHEMBL17007549 | 0.90 | ALDH1A1 (0.65) | ITGB3ITGA2BF2PLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2015-08-20 | — | — | US | disclosed |
| WO-2014047288-A2 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | DOMINGUEZ CELIA (US) | 2014-03-27 | — | — | WO | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | ITGB3 3817/4885ITGA2B 3234/4885F2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.